Well, thank you, Deepak. So let's review in greater detail the financial results for our fiscal ‘24 second quarter. Again, our fiscal Q2 revenues were up 26% with the second quarter of the prior fiscal year. Q2 Security division revenues were up 49%, largely the results of sales growth of our cargo and vehicle inspection products. We also had double-digit revenue growth in our aviation and checkpoint products and related services. Q2 revenues included continued shipments from the $200 million plus cargo contract announced in January ‘23, and initial revenues from the $500 million plus cargo contract announced in March ‘23. Opto sales were down approximately 1% year-over-year. Strong intercompany Opto sales to support anticipated Security division growth were partially offset by reduced third-party revenues as certain Opto customers decreased inventory levels or are experiencing program delays, which we anticipate will continue to impact us for another quarter or so. The Healthcare division sales decreased 4% year-over-year with growth in recurring revenues of SaaS, service, supplies and accessories, along with growth in cardiology product revenues. These increases though were outweighed by a decrease in revenues reported for our largest product family, patient monitoring, in the challenging hospital CapEx environment. The fiscal ‘24 Q2 gross margin of 37.9% was up over 500 basis points from the 32.5% gross margin in Q2 last year. While the gross margin expanded in each division, the most notable improvement was seen in the security division, which experienced a favorable mix of sales along with strong operational execution. Our gross margin will generally fluctuate from period to period based on revenue mix and volume, inflation and impacts of changes in supply chain costs amongst other factors. Moving to operating expenses. We continue to work diligently across each of our divisions to improve efficiency and to prudently manage our SG&A cost structure. Q2 SG&A expenses were $71.6 million or 19.2% of sales compared to 18.3% of sales in Q2 of the prior year. The year-over-year increase was driven by higher compensation costs, including incentive compensation linked to our significant sales growth, increased professional fees, and a higher level of bad debt expense than in the prior year Q2. We expect to leverage our SG&A for fiscal ‘24 where such expenses are expected to decline as a percentage of sales on a full-year basis, implying a lower SG&A run rate in the second half of the 2024 fiscal year then we reported in Q2. Research and development expenses in Q2 of fiscal ‘24 were $16.4 million or 4.4% of sales, compared to $14.5 million or 4.9% of sales from the prior year quarter. We continue to dedicate considerable resources to R&D, particularly in security and healthcare, as we remain focused on innovative product development, which we view as vital to the long-term success of our businesses. We recorded $1 million of restructuring and other charges in Q2 of fiscal 2024, compared to $2.3 million of such charges in Q2 of the prior fiscal year. Moving to interest and taxes. Net interest and other expenses in Q2 increased to $6.5 million in fiscal year ‘24 from $5.2 million in fiscal year ‘23, primarily due to increased interest rates on a higher level of borrowings. We executed an interest rate swap during Q1 of fiscal ‘23 to fix a portion of our floating rate bank debt. Our reported effective tax rate under GAAP was 20.2% in Q2 of fiscal ‘24 compared to 19.5% in Q2 of fiscal ‘23. In Q2 of fiscal ‘24, we recognized a discrete tax benefit of $2.5 million compared to $0.7 million in Q2 of the last fiscal year. Excluding the impact of discrete tax items, our normalized effective tax rate in Q2 of fiscal ‘24 was 25.7% compared to a normalized effective tax rate of 23% in Q2 last year. I will now turn to a discussion of our non-GAAP adjusted operating margin. Overall, our non-GAAP adjusted operating margin in the second quarter of fiscal ‘24 increased to 15.5% from 10.7% in Q2 of fiscal ’23, driven by strength in the Security division. The non-GAAP adjusted operating margin in the Security division expanded to 22.1% in Q2 of this year from 14.7% in Q2 of last year, primarily due to a favorable sales mix and operational improvements. The adjusted operating margin in our Opto division was again solid, increasing to 13.4% in the second quarter of fiscal 2024 from 13.1% in last year's Q2. The Healthcare's division's adjusted operating margin was negligible with the reduction in the division sales. Moving to cashflow. As mentioned on past calls, we expected to invest significant amounts in working capital associated with the anticipated strong growth in security. In Q2, cash used in operations was $23.5 million, primarily due to increases in accounts receivable associated with the revenue growth and inventory increases in preparation for program deliveries under the two large security division contracts announced last year. CapEx in the second quarter was $3.5 million, while depreciation and amortization expense was $10.3 million. Our balance sheet is solid with, modest net leverage of under 1.4x, and significant capacity for investments, acquisitions, and stock buybacks. Aside from $7.5 million of annual required principle payments under our bank term loan, the bulk of our debt matures in fiscal 2027. Finally, turning to guidance. We are increasing both our fiscal ‘24 revenues and non-GAAP diluted EPS guidance. We currently expect our fiscal 2024 revenues to increase more than 19% over revenues in fiscal ‘23, and we anticipate our fiscal 2024 non-GAAP diluted EPS to grow more than 29% over our non-GAAP diluted EPS in fiscal ‘23. This non-GAAP diluted EPS guidance excludes potential impairment restructuring and other charges, amortization of inquired intangible assets and their associated tax effects, as well as discrete tax and other non-recurring items. We currently believe this guidance reflects reasonable estimates. The actual impact on the company's financial results of timing changes on expected revenues, disruptions and increased costs in the supply chain and inflation and interest rates is difficult to predict, and could vary significantly from the anticipated impact currently reflected in our estimates and guidance. Actual revenues and non-GAAP earnings per diluted share could also vary from the guidance indicated above due to other risks and uncertainties discussed in our SEC filings. We continue to remain focused on the growth of our businesses and proactive management of our cost structure. We believe our efforts will enable OSI to continue providing innovative products and solutions. We would like to take this opportunity to thank the global OSI Systems team for its continued dedication in supporting our customers and partners. And at this time, we'd like to open the call to questions.